<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940705-2-00221</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> Appendix M&hyph;I&hyph;B&hyph;3&hyph;a. Will cells (e.g., bone marrow cells) be removed from patients  <!-- PJG 0012 frnewline --> and treated ex vivo? If so, describe the type, number, and intervals at which these  <!-- PJG 0012 frnewline --> cells will be removed.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;3&hyph;b. Will patients be treated to eliminate or reduce the number  <!-- PJG 0012 frnewline --> of cells containing malfunctioning genes (e.g., through radiation or chemotherapy)?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;3&hyph;c. What treated cells (or vector/DNA combination) will be  <!-- PJG 0012 frnewline --> given to patients? How will the treated cells be administered? What volume of  <!-- PJG 0012 frnewline --> cells will be used? Will there be single or multiple treatments? If so, over what  <!-- PJG 0012 frnewline --> period of time?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;3&hyph;d. How will it be determined that new gene sequences have  <!-- PJG 0012 frnewline --> been inserted into the patient's cells and if these sequences are being expressed?  <!-- PJG 0012 frnewline --> Are these cells limited to the intended target cell populations? How sensitive are  <!-- PJG 0012 frnewline --> these analyses?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;3&hyph;e. What studies will be conducted to assess the presence and  <!-- PJG 0012 frnewline --> effects of the contaminants?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;3&hyph;f. What are the clinical endpoints of the study? Are there  <!-- PJG 0012 frnewline --> objections and quantitative measurements to assess the natural history of the  <!-- PJG 0012 frnewline --> disease? Will such measurements be used in patient follow-up? How will patients  <!-- PJG 0012 frnewline --> be monitored to assess specific effects of the treatment on the disease? What is  <!-- PJG 0012 frnewline --> the sensitivity of the analyses? How frequently will follow-up studies be  <!-- PJG 0012 frnewline --> conducted? How long will patient follow-up continue?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;3&hyph;g. What are the major beneficial and adverse effects of  <!-- PJG 0012 frnewline --> treatment that you anticipate? What measures will be taken in an attempt to  <!-- PJG 0012 frnewline --> control or reverse these adverse effects if they occur? Compare the probability  <!-- PJG 0012 frnewline --> and magnitude of deleterious consequences from the disease if recombinant DNA  <!-- PJG 0012 frnewline --> transfer is not used.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;3&hyph;h. If a treated patient dies, what special post-mortem studies  <!-- PJG 0012 frnewline --> will be performed?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Appendix M&hyph;I&hyph;B&hyph;4. Public Health Considerations.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Describe any potential benefits and hazards of the proposed therapy to persons  <!-- PJG 0012 frnewline --> other than the patients being treated. Specifically:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;4&hyph;a. On what basis are potential public health benefits or hazards  <!-- PJG 0012 frnewline --> postulated?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;4&hyph;b. Is there a significant possibility that the added DNA will  <!-- PJG 0012 frnewline --> spread from the patient to other persons or to the environment?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;4&hyph;c. What precautions will be taken against such spread (e.g.,  <!-- PJG 0012 frnewline --> patients sharing a room, health-care workers, or family members)?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;4&hyph;d. What measures will be undertaken to mitigate the risks, if  <!-- PJG 0012 frnewline --> any, to public health?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;4&hyph;e. In light of possible risks to offspring, including vertical  <!-- PJG 0012 frnewline --> transmission, will birth control measures be recommended to patients? Are such  <!-- PJG 0012 frnewline --> concerns applicable to health care personnel?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Appendix M&hyph;I&hyph;B&hyph;5. Qualifications of Investigators and Adequacy of Laboratory  <!-- PJG 0012 frnewline --> and Clinical Facilities.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Indicate the relevant training and experience of the personnel who will be involved  <!-- PJG 0012 frnewline --> in the preclinical studies and clinical administration of recombinant DNA.  <!-- PJG 0012 frnewline --> Describe the laboratory and clinical facilities where the proposed study will be  <!-- PJG 0012 frnewline --> performed. Specifically:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;5&hyph;a. What professional personnel (medical and nonmedical) will  <!-- PJG 0012 frnewline --> be involved in the proposed study and what is their relevant expertise? Provide a  <!-- PJG 0012 frnewline --> two-page curriculum vitae for each key professional person in biographical sketch  <!-- PJG 0012 frnewline --> format (see Appendix M&hyph;III&hyph;E).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;B&hyph;5&hyph;b. At what hospital or clinic will the treatment be given?  <!-- PJG 0012 frnewline --> Which facilities of the hospital or clinic will be especially important for the  <!-- PJG 0012 frnewline --> proposed study? Will patients occupy regular hospital beds or clinical research  <!-- PJG 0012 frnewline --> center beds? Where will patients reside during the follow-up period? What  <!-- PJG 0012 frnewline --> special arrangements will be made for the comfort and consideration of the  <!-- PJG 0012 frnewline --> patients. Will the research institution designate an ombudsman, patient care  <!-- PJG 0012 frnewline --> representative, or other individual to help protect the rights and welfare of the  <!-- PJG 0012 frnewline --> patient?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Appendix M&hyph;I&hyph;C. Selection of the Patients  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Estimate the number of patients to be involved in the proposed study. Describe  <!-- PJG 0012 frnewline --> recruitment procedures and patient eligibility requirements, paying particular  <!-- PJG 0012 frnewline --> attention to whether these procedures and requirements are fair and equitable.  <!-- PJG 0012 frnewline --> Specifically:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;I&hyph;C&hyph;1. How many patients do you plan to involve in the proposed  <!-- PJG 0012 frnewline --> study?  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            